
Following months – or even years – of speculation about the prospects and potential scope of a new US order of a smallpox vaccine from Bavarian Nordic, the Danish biotech has finally won the order.
“The US government today gave the go-ahead for Bavarian Nordic to continue its delivery of the smallpox vaccine Imvamune in coming years, and the vaccine will thus be used to maintain the US bioterror defence system. The new contract of 8 million doses of the vaccine for a total value of USD 228 million also means Bavarian Nordic will maintain its current level of production,” the company writes in a statement and adds:
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app